{"prompt": "['2017N323364_0', 'CONFIDENTIAL', '2019N398531_00', '207626', 'discuss anti-smoking strategies that primary care physicians may be able', 'to', 'provide if participants do not feel capable of discontinuing smoking', 'participants may discontinue smoking at any time during the study and will not', 'have to be withdrawn from the study if they do so.', 'The specific information to be discussed with each participant is provided in the SRM.', '10.', 'STATISTICAL CONSIDERATIONS', '10.1.', 'Hypotheses', 'The primary objective of this study is to compare single inhaler triple therapy', '(FF/UMEC/VI) with tiotropium in participants with COPD who have received tiotropium', 'and continue to have symptoms as measured by CAT >10. The primary endpoint is', 'trough FEV1 at Week 24 (Day 85). The primary analysis is the comparison of this', 'endpoint between FF/UMEC/VI and tiotropium.', 'The null hypothesis is that there is no difference between treatment groups.', 'HO: T1 - T2 = 0', 'The alternative hypothesis is there is a difference between treatment groups.', '-', 'Where T1 and T2 are the treatment means for FF/UMEC/VI and tiotropium, respectively.', '10.2.', 'Sample Size Determination', 'Sample size calculation is based on the primary endpoint of trough FEV1 at Week 12', '(Day 85) and assumes 90 % power, a two-sided 1 % significance level, an estimate of', 'residual standard deviation of 240 mL (based on mixed model repeated measures', '[MMRM] analyses of closed triple Phase IIb study CTT116853 in COPD participants)', 'and a treatment difference of 70 mL. Under these assumptions, in total 702 evaluable', 'participants (351 per treatment group) will be required.', 'It is estimated that approximately 10% of participants will withdraw during the treatment', 'period without providing a Day 85 trough assessment and approximately 8 % of', 'participants will drop out from the 4 week run-in (including those not meeting', 'randomisation criteria). Therefore approximately 848 participants will be enrolled to 4-', 'week run-in in order to have 780 participants randomised.', '10.3.', 'Populations for Analyses', 'For purposes of analysis, the following populations are defined:', '71']['2017N323364_0', 'CONFIDENTIAL', '2019N398531_00', '207626', 'Population', 'Description', 'All Subject Enrolled (ASE)', 'All participants for whom a record exists in the study database,', 'including screen failures and any participant who was not', 'screened but experienced an SAE between the date of informed', 'consent and the planned date of the Screening visit.', 'Intent-to Treat', 'All randomised participants, excluding those who were', '(ITT)', 'randomised in error. A participant who is recorded as a screen', 'or run-in failure and also randomised will be considered to be', 'randomised in error. Any other participant who receives a', 'randomisation number will be considered to have been', 'randomised.', 'Displays will be based on the treatment to which the participant', 'was randomised.', '10.4.', 'Statistical Analyses', '10.4.1.', 'Efficacy Analyses', 'Efficacy analyses will be based on the ITT Population using only data collected on-', 'treatment, unless otherwise specified.', 'Endpoint', 'Statistical Analysis Methods', 'Primary', 'The primary endpoint of trough FEV1 on Day 85 will be analysed for the ITT', 'Population using a mixed model repeated measures (MMRM) analysis, including', 'trough FEV1 recorded at each of visits, Day 28, Day 84 and Day 85. The model', 'will include covariates of baseline FEV1, visit, geographical region, treatment and', 'visit by baseline interaction. A visit by treatment interaction term will also be', 'included to allow treatment effects to be estimated at each visit separately. The', 'variance-covariance matrix will be assumed unstructured.', 'Estimated differences between FF/UMEC/VI and tiotropium will be presented', 'together with 95 % confidence intervals (CIs) for the difference and p-values.', 'A \"tipping point\" sensitivity analysis of trough FEV1 on Day 85 will be conducted', 'for the ITT Population. This will explore the impact of missing data by using', 'differing assumptions regarding the mean treatment effect in participants who', 'discontinue study treatment. Assumptions will include scenarios where', 'participants who discontinue FF/UMEC/VI have a lower treatment effect than', 'those who discontinue TIO. The analysis results will be used to explore the', 'conditions under which the conclusion of superiority no longer holds.', 'Secondary', 'Secondary endpoint change from baseline in trough FEV1 on Day 28 and Day', '84 will be part of the primary endpoint analysis (MMRM).', '72']\n\n###\n\n", "completion": "END"}